OptimizeRx Corp

OptimizeRx Corp

OptimizeRx was founded in 2006 and went public via a reverse merger in 2009, establishing its headquarters in Rochester, Michigan. CEO Will Febbo joined in 2008 and retooled the company from a consumer savings-card distributor into an enterprise digital health platform — one that pharmaceutical manufacturers use to deliver copay savings, clinical education, and brand messaging within the electronic health record systems that doctors already use. The pivot embedded the company in a distribution moat most health-tech firms lack: real-time integration with the prescribing moment. The platform spans three core channels across the treatment journey. Financial messaging surfaces affordability options — copay cards, vouchers, patient assistance programs — directly inside EHR workflows like e-prescribing. Clinical education delivers peer-reviewed research and therapy guidelines to clinicians at the moment they make treatment decisions. A newer AI-driven care-guidance module analyzes structured and unstructured patient data inside the EHR to recommend therapies and identify clinical-trial candidates. Major pharmaceutical clients include Novartis, Pfizer, and Lilly, and the company has established integrations with leading EHR platforms such as Epic and Cerner. Revenue comes almost entirely from U.S. pharma brands paying to place their messages in these workflows, and the network now spans more than half of all practicing prescribers. The company employs roughly 124 people and operates as a publicly traded entity with February 2024 market capitalization near $200 million. It maintains its Rochester-area headquarters and closed its acquisition of Medisafe, a medication-adherence platform with 10 million registered patients, in September 2023 — a deal that extended the OptimizeRx network into the post-prescription patient experience for the first time. This added a direct-to-patient channel alongside the longstanding physician-facing EHR network, creating a closed-loop communication architecture between brand messaging at the point of care and ongoing patient engagement after the script is written. Most health-tech companies sell into providers or payers. OptimizeRx is structurally different: it sells exclusively to pharmaceutical manufacturers while its platform lives inside the tools clinicians already use. That makes the company a neutral distribution layer rather than another login for doctors. The business model aligns the company's incentives with pharma's commercial objectives, not with hospital procurement cycles, and its integration depth with EHR incumbents creates switching costs any competitor would struggle to replicate.